SIG
ALXN

Stanford Investment Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Stanford Investment Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-244
Closed -$30K – 330
2016
Q4 		$30K Hold
244
– – 0.01% 198
2016
Q3 		$2K Hold
244
– – ﹤0.01% 400
2016
Q2 		$28K Buy
244
+37
+18% +$5.25K 0.01% 207
2016
Q1 		$29K Buy
207
+33
+19% +$4.84K 0.02% 200
2015
Q4 		$32K Hold
174
– – 0.02% 174
2015
Q3 		$27K Hold
174
– – 0.02% 194
2015
Q2 		$31K Hold
174
– – 0.02% 185
2015
Q1 		$30K Hold
174
– – 0.02% 188
2014
Q4 		$32K Buy
+174
New +$32.2K 0.03% 183

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Stanford Investment Group's ALXN Position: Q1 2017 in Review

Stanford Investment Group sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 244 shares — an estimated $30K sold.

Stanford Investment Group first reported a position in ALXN in Q4 2014 and held it in 9 quarters. The position peaked at $32K in Q4 2015. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Stanford Investment Group reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Stanford Investment Group sold 244 Alexion Pharmaceuticals shares in Q1 2017, an estimated $30K.
  • Stanford Investment Group first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 9 quarters.
  • Stanford Investment Group's Alexion Pharmaceuticals position peaked at $32K in Q4 2015.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Stanford Investment Group's 13F filing for Q1 2017.